Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858205 · ClinicalTrials.gov registry record · NA
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
A NA study of Plasma Cell Myeloma and Metastatic Malignant Neoplasm in the Bone, sponsored by University of Southern California.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT03858205: Recruiting NA study of Plasma Cell Myeloma and Metastatic Malignant Neoplasm in the Bone, sponsored by University of Southern California.
NCT03858205 is a NA study of Plasma Cell Myeloma and Metastatic Malignant Neoplasm in the Bone that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 100 participants, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (51% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03858205, a NA study of Plasma Cell Myeloma and Metastatic Malignant Neoplasm in the Bone, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.
Primary Outcome
Pain will be measured using the Brief Pain Inventory (BPI).
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- RADIATION Radiation Therapy
Study Locations (9)
California
- City of Hope - Duarte
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- University of Minnesota - Masonic Cancer Center - Minneapolis
New York
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2027-03-11 |
| Phase | NA |
What NCT03858205 shows while recruiting
NCT03858205 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03858205 lists 9 locations in 6 states (California, Georgia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03858205 about?
NCT03858205 is a clinical study titled "Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma". This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherap...
What is the current status of trial NCT03858205?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2019-03-11. Estimated completion is 2027-03-11.
What conditions does trial NCT03858205 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma, Metastatic Malignant Neoplasm in the Bone, Bone Pain.
What interventions are being tested in trial NCT03858205?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03858205?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03858205 being conducted?
This trial has 9 study locations across California, Georgia, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03858205's enrollment target sits among peer trials
100 13th of 32 higher than 18 of 32 other Plasma Cell Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plasma Cell Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
-
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
ACTIVE NOT RECRUITING · NA
-
Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy
COMPLETED · NA
-
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
COMPLETED · NA
-
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RECRUITING · Phase 3
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI